 |
|
Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients
Man-Fung Yuen, Wan-Long Chuang, Cheng-Yuan Peng, Wen-Juei Jeng, Wei-Wen Su, Ting-Tsung Chang, Chi-Yi Chen, Yao-Chun Hsu, Guy De La Rosa, Alaa Ahmad, Ed Luo, Annie L. Conery
Clin Mol Hepatol. 2024;30(3):375-387. Published online 2024 Mar 26 DOI: https://doi.org/10.3350/cmh.2023.0535
|
|
Citations to this article as recorded by
 Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure
Hae Lim Lee, Jeong Won Jang
Clinical and Molecular Hepatology.2024;[Epub] CrossRef
|